Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Top 100 Creative Companies

What does the new NHS plan mean for pharma?

Steve How and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of the NHS Long-term Plan

Wilmington Healthcare

- PMLiVE

European biosimilars hit AbbVie’s Humira revenues in Q4

Strong full year growth, but M&A speculation will linger

- PMLiVE

Ministerial revolt looming over ‘no-deal’ Brexit risk

Airbus CEO says no-deal Brexit could force it to relocate

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Blue Latitude Health

- PMLiVE

Launch trends 2019

Thunicia Moodley from Syneos Health talks trends

Drug launches to watch in 2019

13 market-changing drugs expected to hit the European market this year

- PMLiVE

How to pay for very high cost, curative drugs? ICER and NICE put their heads together

Three HTA bodies seek answers to future value models

- PMLiVE

UK unveils new antibiotic buying plan, pharma incentives

Health minister compares upfront payment model to Spotify

- PMLiVE

Advaxis shaken by another FDA hold on cervical cancer vaccine

Suspends enrolment into pivotal phase 3 trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links